DK3558335T3 - Caspase-1 inhibition and uses thereof for prevention and treatment of neurological conditions - Google Patents

Caspase-1 inhibition and uses thereof for prevention and treatment of neurological conditions Download PDF

Info

Publication number
DK3558335T3
DK3558335T3 DK17883876.9T DK17883876T DK3558335T3 DK 3558335 T3 DK3558335 T3 DK 3558335T3 DK 17883876 T DK17883876 T DK 17883876T DK 3558335 T3 DK3558335 T3 DK 3558335T3
Authority
DK
Denmark
Prior art keywords
caspase
inhibition
prevention
treatment
neurological conditions
Prior art date
Application number
DK17883876.9T
Other languages
English (en)
Inventor
Andréa C Leblanc
Original Assignee
Casp Aid Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Casp Aid Inc filed Critical Casp Aid Inc
Application granted granted Critical
Publication of DK3558335T3 publication Critical patent/DK3558335T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
DK17883876.9T 2016-12-23 2017-12-20 Caspase-1 inhibition and uses thereof for prevention and treatment of neurological conditions DK3558335T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662438529P 2016-12-23 2016-12-23
US201762579936P 2017-11-01 2017-11-01
PCT/CA2017/051548 WO2018112626A1 (en) 2016-12-23 2017-12-20 Caspase-1 inhibition and uses thereof for prevention and treatment of neurological conditions

Publications (1)

Publication Number Publication Date
DK3558335T3 true DK3558335T3 (da) 2023-07-24

Family

ID=62624456

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17883876.9T DK3558335T3 (da) 2016-12-23 2017-12-20 Caspase-1 inhibition and uses thereof for prevention and treatment of neurological conditions

Country Status (13)

Country Link
US (2) US11160788B2 (da)
EP (1) EP3558335B1 (da)
JP (1) JP7213555B2 (da)
KR (1) KR102590456B1 (da)
CN (1) CN110545835A (da)
AU (1) AU2017383127A1 (da)
CA (1) CA3047836C (da)
DK (1) DK3558335T3 (da)
ES (1) ES2950100T3 (da)
FI (1) FI3558335T3 (da)
PL (1) PL3558335T3 (da)
PT (1) PT3558335T (da)
WO (1) WO2018112626A1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3176737A1 (en) 2020-05-01 2021-11-04 Thomas M. FISHBEIN Methods for treating covid-19
EP4165037A4 (en) 2020-06-10 2024-07-03 Aligos Therapeutics Inc ANTIVIRAL COMPOUNDS FOR THE TREATMENT OF CORONAVIRUS, PICORNAVIRUS AND NOROVIRUS INFECTIONS
IL309732A (en) 2021-07-09 2024-02-01 Aligos Therapeutics Inc Antiviral compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1064298E (pt) 1998-03-19 2009-01-02 Vertex Pharma Inibidores de caspasas
IL152393A (en) 2000-04-24 2008-03-20 Vertex Pharma Process for making aspartic acid acetal derivatives
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
KR100538780B1 (ko) 2002-09-10 2005-12-23 주식회사 브레인트로피아 미노사이클린을 유효성분으로 함유하는 치매 및 기억력감퇴의 예방 및 치료용 조성물
JP4898658B2 (ja) 2004-03-12 2012-03-21 バーテックス ファーマシューティカルズ インコーポレイテッド アスパラギン酸アセタールカスパーゼ阻害剤の製造のための方法および中間体
CN1980658A (zh) 2004-05-27 2007-06-13 沃泰克斯药物股份有限公司 治疗自身炎性疾病的ice抑制剂
PL2245026T3 (pl) 2008-02-07 2013-01-31 Boehringer Ingelheim Int Spirocykliczne heterocykle, leki zawierające te związki, ich zastosowanie i sposób ich produkcji
US9365612B2 (en) 2010-01-29 2016-06-14 United States Of America As Represented By The Secretary, Department Of Health And Human Services Caspase inhibitors
WO2012061786A1 (en) 2010-11-05 2012-05-10 Brandeis University Ice cleaved alpha-synuclein a biomarker
ES2907620T3 (es) 2011-07-18 2022-04-25 Univ Kentucky Res Found Protección de células de la degeneración inducida por ARN Alu e inhibidores para proteger células
US9956260B1 (en) 2011-07-22 2018-05-01 The J. David Gladstone Institutes Treatment of HIV-1 infection and AIDS

Also Published As

Publication number Publication date
CA3047836C (en) 2024-02-06
ES2950100T3 (es) 2023-10-05
KR102590456B1 (ko) 2023-10-17
CN110545835A (zh) 2019-12-06
PT3558335T (pt) 2023-07-20
US20190328709A1 (en) 2019-10-31
US11160788B2 (en) 2021-11-02
JP7213555B2 (ja) 2023-01-27
US20220054454A1 (en) 2022-02-24
WO2018112626A1 (en) 2018-06-28
EP3558335A1 (en) 2019-10-30
JP2020502282A (ja) 2020-01-23
KR20190099497A (ko) 2019-08-27
AU2017383127A1 (en) 2019-07-11
CA3047836A1 (en) 2018-06-28
PL3558335T3 (pl) 2023-08-21
FI3558335T3 (fi) 2023-07-19
EP3558335B1 (en) 2023-04-19
EP3558335A4 (en) 2020-09-09

Similar Documents

Publication Publication Date Title
IL266273A (en) Systems and methods for treating excess fluids
IL298690B1 (en) Preparations and methods for suppressing masp-3 for the treatment of various diseases and conditions
GB2554629B (en) Prevention and treatment of microbial infections
ZA201908165B (en) Compounds for the prevention and treatment of diseases and the use thereof
DK3558280T3 (da) Forebyggelse og behandling af migræne
ZA201901055B (en) Treatment and prevention of sleep disorders
IL263477A (en) Compositions and methods for the treatment or prevention of oxalate-related disorders
DK3558335T3 (da) Caspase-1 inhibition and uses thereof for prevention and treatment of neurological conditions
ZA202000558B (en) Prevention and/or treatment of neurodegenerative disease
EP3723742C0 (fr) Utilisation de la fluoroethylnormemantine pour la prevention et le traitement de l'anxiete
PL3183003T3 (pl) SPOSOBY ZAPOBIEGANIA l/LUB LECZENIA ZAKAŻENIA
HK1243961A1 (zh) 炎性病况的預防和治療
PL3504163T3 (pl) Oczyszczanie ścieków
EP3377062C0 (en) AMINONAPHHOQUINONE COMPOUNDS FOR THE TREATMENT AND/OR PREVENTION OF FIBROSIS DISEASES
GB201615298D0 (en) Treatment and prevention of Malaria
GB201719969D0 (en) Prevention and/or treatment of neurodegenerative disease
GB201815000D0 (en) Treatment of hypothroidism and related conditions
GB201522828D0 (en) Prevention and treatment of glaucoma
ITUB20160141A1 (it) Composizione per la prevenzione ed il trattamento di cefalee primarie
SG11201705889VA (en) Prevention or Treatment of Uratic or Gouty Diseases
GB201519483D0 (en) Prevention and treatment of microbial infections
GB201518252D0 (en) Prevention and treatment of microbial infections
GB201513047D0 (en) Prevention and treatment of microbial infections
GB201511576D0 (en) Prevention and treatment of microbial infections
GB201509654D0 (en) Prevention and treatment of microbial infections